ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 0810 • ACR Convergence 2021

    Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis

    Carol Hitchon1, Marie-France Valois2, Orit Schieir3, Susan Bartlett2, Louis Bessette4, Gilles Boire5, Glen Hazlewood6, Edward Keystone7, Janet Pope8, Carter Thorne9, Diane Tin10, Vivian Bykerk11 and Canadian Early Arthritis Cohort (CATCH) Investigators12, 1University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montréal, QC, Canada, 3Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10The Arthritis Program Research Group, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Canadian Early Arthritis Cohort, Toronto, ON, Canada

    Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…
  • Abstract Number: 0833 • ACR Convergence 2021

    Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study

    Torsten Witte1, Uta Kiltz2, Florian Haas3, Elke Riechers4, Ulrich Prothmann5, Daniela Adolf6, Carsten Holland7, Rouven Hecht8, Alexander Rössler7, Kirsten Famulla8, Konrad Götz8 and Klaus Krüger9, 1Hannover Medical School, Hannover, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 3Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, 4Department for Rheumatology and Immunology, Hannover Medical University, Hannover, 5Knappschaftsklinikum Saar, Püttlingen, Germany, 6StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, 8AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 9Rheumatological Practice Center, Munich, Germany

    Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
  • Abstract Number: 0853 • ACR Convergence 2021

    A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap

    Craig Willers1, Tom Lynch1, Vibhasha Chand2, Mohammad Islam3, Marissa Lassere4, Helen Keen5, Tony Kenna6, Susan Lester7, Ranjeny Thomas8, Premarani Sinnathurai9, Mihir Wechalekar10, Ashley Fletcher11, Daniel Lightowler12, Sheeraz Mohd13, Nishta Ramnoruth14, Carlee Ruediger15, Helen Weedon16 and Lyn March17, 1Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, 2Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 3Information and Communications Technology, University of Sydney, Sydney, Australia, 4St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, 5University of Western Australia, Daglish, Australia, 6Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, 7Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, 8University of Queensland, Diamantina Institute, Brisbane, Australia, 9Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, 10Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, 11Cabrini Health, Malvern, Australia, 12Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, 13Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, 14Diamantina Institute, University of Queensland, Brisbane, Australia, 15University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, 16Flinders University, Bedford Park, Australia, 17Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia

    Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
  • Abstract Number: 0897 • ACR Convergence 2021

    Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis

    Tae-Han Lee1, Bon San Koo2, Bora Nam3, Seunghun Lee4, Kyung Bin Joo4 and Tae-Hwan Kim3, 1Keimyung University Dongsan Hospital, Daegu, Republic of Korea, 2Inje University Seoul Paik Hospital, Seoul, Republic of Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 4Hanyang University Hospital, Seoul, Republic of Korea

    Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
  • Abstract Number: 0932 • ACR Convergence 2021

    Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists

    Stefan Kleinert1, Peter Bartz-Bazzanella2, Cay Von der Decken3, Kirsten Karberg4, Florian Schuch5, Georg Gauler6, Patrick Wurth7, Susanna Späthling-Mestekemper8, Christoph Kuhn9, Fabian Proft10, Denis Poddubnyy11, Mathias Englbrecht12 and Wolfgang Vorbrüggen13, 1Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 2Rhein-Maas Klinikum, Wuerselen, Germany, 3Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, 4Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, 5Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, 6rheumapraxis, Osnabrck, Germany, 7Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, 8Rheumapraxis München, München, Germany, 9Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, 10Charité University Medicine Berlin, Berlin, Germany, 11Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 12Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, 13Verein zur Förderung der Rheumatologie e.V., Würselen, Germany

    Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…
  • Abstract Number: 1158 • ACR Convergence 2021

    Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up

    Kaleb Michaud1, Sofia Pedro2, Victoria Jasion3, Holly Budlong4, Jessica Suboticki5, Frederick Wolfe6 and Patricia Katz7, 1University of Nebraska Medical Center, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3AbbVie, Overland Park, KS, 4AbbVie, Minneapolis, MN, 5AbbVie Inc., North Chicago, IL, 6National Data Bank for Rheumatic Diseases, Wichita, KS, 7University of California San Francisco, San Francisco, CA

    Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness…
  • Abstract Number: 1197 • ACR Convergence 2021

    Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation

    Adelina Plachokova1, Jill Hadisurya1, Julia van Bergen2 and Rogier Thurlings3, 1Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, Netherlands, 2Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, 3Radboud University Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Transversal cohort studies demonstrated a possible association between periodontal disease (PD) and rheumatoid arthritis (RA). However it is unknown how this association evolves during…
  • Abstract Number: 1299 • ACR Convergence 2020

    Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity

    Daphne Lew1, Xinliang Huang2, Sara Kellahan2, Hong Xian3, Seth Eisen4 and Alfred Kim5, 1Washington University in St. Louis School of Medicine, Saint Louis, MO, 2Division of Rheumatology, Washington University in St. Louis School of Medicine, St. Louis, 3Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, 4Washington University School of Medicine, St Louis, MO, 5Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…
  • Abstract Number: 1312 • ACR Convergence 2020

    Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis

    Gillian Fitzgerald1, George Tomlinson2, Steve Ramkissoon3, Sophie Wojcik4, Robert Inman5 and Nigil Haroon6, 1Toronto Western Hospital, Toronto, ON, Canada, 2Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, 3UHN, Toronto, ON, Canada, 4UHN, Montreal, QC, Canada, 5University Health Network, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…
  • Abstract Number: 1354 • ACR Convergence 2020

    The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis

    Mark Siderius1, Freke Wink1, Anneke Spoorenberg1 and Suzanne Arends1, 1University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
  • Abstract Number: 0272 • ACR Convergence 2020

    Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold

    Eric Morand1, Vera Golder2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Yi-Hsing Chen16, Yanjie Hao17, Zhuoli Zhang17, Jun Kikuchi18, Tsutomu Takeuchi19, Chak Sing Lau20, Zhanguo Li21, Alberta Hoi22, Mandana Nikpour23 and Rangi Kandane-Rathnayake2, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Monash University, Clayton, Victoria, Australia, 3Chiang Mai University Hospital, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 17Peking University First Hospital, Beijing, China (People's Republic), 18Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 19Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 20Hong Kong University, Hong Kong, Hong Kong, 21Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 22Monash University, Melbourne, Victoria, Australia, 23The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia

    Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
  • Abstract Number: 1451 • ACR Convergence 2020

    Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE

    Michelle Petri1, Laurence Magder2 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
  • Abstract Number: 0302 • ACR Convergence 2020

    Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets

    Kieran Manion1, Dennisse Bonilla2, Dafna Gladman1, Murray Urowitz3, Zahi Touma4 and Joan Wither2, 1Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
  • Abstract Number: 1467 • ACR Convergence 2020

    Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

    Andre Luquini1, Yufei Zheng2, Hui Xie3, Catherine Backman1, Pamela Rogers3, Alex Kwok3, Astrid Knight3, Monique Gignac4, Dianne Mosher5, Linda Li1, John Esdaile6, Carter Thorne7 and Diane Lacaille1, 1University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, 2Simon Fraser University / Arthritis Research Canada, Richmond, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Institute for Work & Health / University of Toronto, Toronto, ON, Canada, 5University of Calgary, Calgary, AB, Canada, 6Arthritis Research Canada, Vancouver, BC, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada

    Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of…
  • Abstract Number: 0307 • ACR Convergence 2020

    Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis

    Alexis Ogdie1, Martin Rozycki2, Theresa Arndt2, Cheng Shi3, Nina Kim4 and Peter Hur3, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2HVH Precision Analytics, LLC, Wayne, PA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4The University of Texas at Austin; Baylor Scott and White Health, Austin, TX

    Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology